A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer

European Journal of Cancer

Volumn 48, Issue 18, 2012, Pages 3396-3404

  Hayashi, Yuki ^a   Xiao, Lianchun ^a   Suzuki, Akihiro ^a   Blum, Mariela A ^a   Sabloff, Bradley ^a   Taketa, Takashi ^a   Maru, Dipen M ^a   Welsh, James ^a   Lin, Steven H ^a   Weston, Brian ^a   Lee, Jeffrey H ^a   Bhutani, Manoop S ^a   Hofstetter, Wayne L ^a   Swisher, Stephen G ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Nomogram; Oesophageal cancer; Prognosis; Trimodality therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; FLUOROPYRIMIDINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS CANCER; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT LYMPH NODE; MALIGNANT NEOPLASTIC DISEASE; NOMOGRAM; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREMEDICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE FRACTIONATION; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NOMOGRAMS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84869493016     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.06.020     Document Type: Article

References (23)

1. C. Mariette, G. Taillier, I. Van Seuningen, and J.P. Triboulet Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma Ann Thorac Surg 78 4 2004 1177 1183 S0003497504004680 [pii] 10.1016/j.athoracsur.2004.02.068 [doi] (Pubitemid 39303830)
2. T.W. Rice, V.W. Rusch, and C. Apperson-Hansen Worldwide esophageal cancer collaboration Dis Esophagus 22 1 2009 1 8 http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=19196264, DES901 [pii] 1111/j.1442-2050.2008.00901.x
3. W. Hofstetter, S.G. Swisher, and A.M. Correa Treatment outcomes of resected esophageal cancer Ann Surg 236 3 2002 376 384 discussion 384-375. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=12192324
4. K.M. Sjoquist, B.H. Burmeister, and B.M. Smithers Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis Lancet Oncol 12 7 2011 681 692 Epub: S1470-2045(11)70142-5 [pii] 10.1016/S1470-2045(11)70142-5 [doi]
5. J. Tepper, M.J. Krasna, and D. Niedzwiecki Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 J Clin Oncol 26 7 2008 1086 1092 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=18309943
6. T.N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, and T.P. Hennessy A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N Engl J Med 335 7 1996 462 467 http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 8672151 (Pubitemid 26269945)
7. Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer. Results from a multicenter randomized phase III study. Am Soc Clin Oncol. Chicago, ILL: ASCO, 2010:15s.
8. N.P. Rizk, E. Venkatraman, and M.S. Bains American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma J Clin Oncol 25 5 2007 507 512 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=17290058 (Pubitemid 350002956)
9. T.T. Wu, L.R. Chirieac, and S.C. Abraham Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome Am J Surg Pathol 31 1 2007 58 64 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=17197919 (Pubitemid 46036902)
10. L.R. Chirieac, S.G. Swisher, and J.A. Ajani Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation Cancer 103 7 2005 1347 1355 http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=15719440 (Pubitemid 40410728)
11. G.W. Dittrick, J.M. Weber, and R. Shridhar Meredith 2011 KL. Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy Ann Surg Oncol http://www.ncbi.nlm.nih.gov/pubmed/22045465, 10.1245/s10434-011- 2078-4
12. J.G. Gaca, R.P. Petersen, and B.L. Peterson Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma Ann Surg Oncol 13 3 2006 340 346 http://www.ncbi.nlm.nih.gov/pubmed/16485154, 10.1245/ASO.2006.02.023 (Pubitemid 43255917)
13. P. Gaur, B. Sepesi, and W.L. Hofstetter A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients Ann Surg 252 4 2010 611 61710 1097/SLA.0b013e3181f56419 [doi] 00000658-201010000-00006 [pii]
14. J.A. Ajani, J.S. Barthel, and D.J. Bentrem Esophageal and esophagogastric junction cancers J Natl Compr Canc Netw 9 8 2011 830 887 http://www.ncbi.nlm. nih.gov/pubmed/21900218, 9/8/830 [pii]
15. F. Greene, D. Page, and I. Fleming AJCC Cancer Staging Manual 6th ed. 2002 Springer New York
16. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 4 1996 361 387 10.1002/(SICI)1097- 0258(19960229)15:4 <361::AID-SIM168>3.0.CO;2-4 [doi] (Pubitemid 26072233)
17. E. Bollschweiler, A.H. Holscher, and R. Metzger Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer Future Oncol 6 1 2010 25 35 10.2217/fon.09.133 [doi]
18. M. Okada, T. Murakami, and S. Kumano Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer Ann Nucl Med 23 1 2009 73 80 10.1007/s12149-008-0209-1 [doi]
19. H.L. van Westreenen, M. Westerterp, and P.M. Bossuyt Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer J Clin Oncol 22 18 2004 3805 3812 http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list- uids=15365078 (Pubitemid 41095222)
20. Y. Gu, S.G. Swisher, and J.A. Ajani The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation Cancer 106 5 2006 1017 1025 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=16456809
21. E. Bollschweiler, S. Besch, and U. Drebber Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer Ann Surg Oncol 17 12 2010 3187 3194 10.1245/s10434-010-1196-8 [doi]
22. J.N. Waldron, R.W. Gilbert, and L. Eapen Results of an Ontario Clinical Oncology Group prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer J Clin Oncol 29 Suppl. 2011 5504 abstract
23. A. Suzuki, L. Xiao, and Y. Hayashi Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy Cancer 2011 http://www.ncbi.nlm.nih.gov/pubmed/ 21456015, 10.1002/cncr.26122